🧫

Endothelin-1 receptor A antagonist rescue experiment

active
experiment Created: 2026-04-06T12:34:31 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-2f9cf4aa-e144-410d-8e04-6132dd045802
🧫 Experiment Protocol ValidationAlzheimer's diseaseCD2APmiceproposed
Treatment of CD2AP mutant mice with endothelin-1 receptor A antagonists to test whether blocking this signaling pathway could rescue the cerebrovascular impairments. The experiment aimed to identify potential therapeutic targets for the vascular dysfunction caused by CD2AP loss. Results showed partial rescue of vascular impairments, but only in male mice, highlighting sex-specific therapeutic responses.
PRIMARY OUTCOME
rescue of vascular impairments
EXPECTED OUTCOMES
1. The intervention targeting CD2AP shifts rescue of vascular impairments in the predicted direction relative to the matched control arm. 2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects. 3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (rescue of vascular impairments) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CD2AP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure rescue of vascular impairments together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Treatment of CD2AP mutant mice with endothelin-1 receptor A antagonists to test whether blocking this signaling pathway could rescue the cerebrovascular impairments. The experiment aimed to identify potential therapeutic targets for the vascular dysfunction ca
🧫 Experiment Extras
PATHWAY
endothelin-1 signaling
MARKET PRICE
$0.50
STATUS
proposed
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.